Multivariate analysis of factors associated with infliximab discontinuation due to SLR or SAE
| Factor | OR | CI for OR | P value |
| TDM never tested | 8.0 | 3.8 to 17.0 | <0.01 |
| Pre-TDM era | 0.65 | 0.3 to 1.4 | 0.28 |
| Previous exposure to biologic | 4.4 | 1.8 to 10.7 | <0.01 |
| Total duration of follow-up | 1.01 | 0.99 to 1.02 | 0.07 |
SAE, serious adverse event; SLR, secondary loss of response; TDM, therapeutic drug monitoring.